2022--provirex--hamburg-researchers-want-to-be-able-to-cure-hiv-soon---magazine--healty-and-sport-news Access

Preclinical data showed the enzyme has no measurable cytotoxic or genotoxic side effects, making it a viable candidate for human testing. 3. 2022 Milestones: The Hamburg Therapy Hub

In 2022, Hamburg emerged as a primary hub for curative HIV research following significant investment in , a biotech startup utilizing "designer recombinase" technology. Unlike traditional antiretroviral therapy (ART) which only suppresses viral replication, the Brec1 recombinase acts as a molecular scalpel to precisely excise integrated HIV-1 DNA from the host genome. This paper details the 2022 expansion of Hamburg’s "Therapy Hub," the underlying Brec1 technology, and the transition toward Phase Ib/IIa clinical trials. 1. The Challenge: Beyond Viral Suppression Preclinical data showed the enzyme has no measurable

In October 2022, PROVIREX announced a major expansion in Hamburg’s . The Challenge: Beyond Viral Suppression In October 2022,

Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally. " the underlying Brec1 technology